Independent Research Guide
Where BL-04 appears on the label
The supplied panel names Bifidobacterium lactis BL-04 within the 20 mg proprietary probiotic blend alongside L. paracasei and L. reuteri. The blend is described as 3.5 billion CFU at manufacture, but the BL-04 share of that total is not disclosed.
Species, strain and product are different levels of identity
“Bifidobacterium lactis” is broader than “Bifidobacterium lactis BL-04.” Probiotic research often depends on a defined strain because functional properties can differ between strains even within the same species.
For that reason, evidence from a named strain such as HN019 is useful background on the species but is not direct clinical evidence for BL-04.
What oral-health research on B. lactis can tell us
A randomized clinical trial has studied B. lactis HN019 as an adjunct in periodontal treatment. That research demonstrates that a B. lactis strain has been investigated in a dental context. It does not establish that BL-04 produces the same result or that the ProDentim blend reproduces the study.
How we apply the evidence
Our ingredient pages use HN019 research only to illustrate the broader scientific interest in bifidobacteria and oral health. We explicitly mark the strain mismatch rather than presenting the paper as a ProDentim trial.
If direct BL-04 oral-health trials become available and are relevant to the label dose and delivery, they should be evaluated on their own merits.
Related reading
Sources & further reading
- PubMed: B. lactis HN019 periodontal trial — Different strain (HN019), therefore not direct BL-04 evidence.